{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T03:01:06Z","timestamp":1777518066726,"version":"3.51.4"},"reference-count":35,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,3,1]],"date-time":"2017-03-01T00:00:00Z","timestamp":1488326400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"Beijing Health System High Level Health Technical Personnel Training Plan","award":["2013-2-007"],"award-info":[{"award-number":["2013-2-007"]}]}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Letters"],"published-print":{"date-parts":[[2017,3]]},"DOI":"10.1016\/j.canlet.2016.12.010","type":"journal-article","created":{"date-parts":[[2016,12,18]],"date-time":"2016-12-18T18:34:07Z","timestamp":1482086047000},"page":"70-77","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":24,"special_numbering":"C","title":["Rocaglamide breaks TRAIL-resistance in human multiple myeloma and acute T-cell leukemia in\u00a0vivo in a mouse xenogtraft model"],"prefix":"10.1016","volume":"389","author":[{"given":"Yin","family":"Wu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marco","family":"Giaisi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rebecca","family":"K\u00f6hler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wen-Ming","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter H.","family":"Krammer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7365-7113","authenticated-orcid":false,"given":"Min","family":"Li-Weber","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.canlet.2016.12.010_bib1","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1038\/nrc2465","article-title":"The TRAIL apoptotic pathway in cancer onset, progression and therapy","volume":"8","author":"Johnstone","year":"2008","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.canlet.2016.12.010_bib2","doi-asserted-by":"crossref","first-page":"2839","DOI":"10.1200\/JCO.2009.25.1991","article-title":"Phase I dose-escalation study of recombinant human Apo2L\/TRAIL, a dual proapoptotic receptor agonist, in patients with advanced cancer","volume":"28","author":"Herbst","year":"2010","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.canlet.2016.12.010_bib3","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1200\/JCO.2009.25.4847","article-title":"Phase 1b study of dulanermin (recombinant human Apo2L\/TRAIL) in combination with paclitaxel, carboplatin, and bevacizumab in patients with advanced non-squamous non-small-cell lung cancer","volume":"28","author":"Soria","year":"2010","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.canlet.2016.12.010_bib4","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1038\/cdd.2015.174","article-title":"Onto better TRAILs for cancer treatment","volume":"23","author":"de Miguel","year":"2016","journal-title":"Cell Death Differ."},{"key":"10.1016\/j.canlet.2016.12.010_bib5","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.ctrv.2008.11.006","article-title":"TRAIL receptor signalling and modulation: are we on the right TRAIL?","volume":"35","author":"Mahalingam","year":"2009","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.canlet.2016.12.010_bib6","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1111\/j.1745-7254.2005.00206.x","article-title":"Antitumor activity of a novel recombinant mutant human tumor necrosis factor-related apoptosis-inducing ligand","volume":"26","author":"Fang","year":"2005","journal-title":"Acta Pharmacol. Sin."},{"key":"10.1016\/j.canlet.2016.12.010_bib7","first-page":"1857","article-title":"Phase Ib study of recombinant circularly permuted TRAIL (CPT) in relapsed or refractory multiple myeloma patients","volume":"120","author":"Chen","year":"2012","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"10.1016\/j.canlet.2016.12.010_bib8","first-page":"78","article-title":"Recombinant circularly permuted TRAIL (CPT) for the treatment of relapsed or refractory multiple myeloma: an open-label, multicenter phase II clinical trial","volume":"120","author":"Chen","year":"2012","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"10.1016\/j.canlet.2016.12.010_bib9","doi-asserted-by":"crossref","first-page":"3456","DOI":"10.1172\/JCI61188","article-title":"Molecular pathogenesis of multiple myeloma and its premalignant precursor","volume":"122","author":"Kuehl","year":"2012","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.canlet.2016.12.010_bib10","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1002\/ajh.23822","article-title":"A\u00a0multicenter, open-label phase II study of recombinant CPT (Circularly Permuted TRAIL) plus thalidomide in patients with relapsed and refractory multiple myeloma","volume":"89","author":"Geng","year":"2014","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.canlet.2016.12.010_bib11","first-page":"1","article-title":"Chemistry and biology of rocaglamides (= flavaglines) and related derivatives from aglaia species (meliaceae)","volume":"94","author":"Ebada","year":"2011","journal-title":"Prog. Chem. Org. Nat. Prod."},{"key":"10.1016\/j.canlet.2016.12.010_bib12","doi-asserted-by":"crossref","unstructured":"M. Li-Wber, Molecular mechanisms and anti-cancer aspects of the medicinal phytochemicals rocaglamides (=flavaglines), Int. J. Cancer. 137(201) 1791\u20131799.","DOI":"10.1002\/ijc.29013"},{"key":"10.1016\/j.canlet.2016.12.010_bib13","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1002\/ijc.22883","article-title":"The traditional Chinese herbal compound rocaglamide preferentially induces apoptosis in leukemia cells by modulation of mitogen-activated protein kinase activities","volume":"121","author":"Zhu","year":"2007","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.canlet.2016.12.010_bib14","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1038\/cdd.2010.99","article-title":"Rocaglamide breaks TRAIL resistance in HTLV-1-associated adult T-cell leukemia\/lymphoma by translational suppression of c-FLIP expression","volume":"18","author":"Bleumink","year":"2011","journal-title":"Cell Death Differ."},{"key":"10.1016\/j.canlet.2016.12.010_bib15","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1016\/j.chembiol.2012.07.012","article-title":"The\u00a0natural anticancer compounds rocaglamides inhibit the Raf-MEK-ERK pathway by targeting prohibitin 1 and 2","volume":"19","author":"Polier","year":"2012","journal-title":"Chem. Biol."},{"key":"10.1016\/j.canlet.2016.12.010_bib16","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1002\/ijc.29009","article-title":"Targeting CDK9 by wogonin and related natural flavones potentiates the anti-cancer efficacy of the Bcl-2 family inhibitor ABT-263","volume":"136","author":"Polier","year":"2015","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.canlet.2016.12.010_bib17","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1084\/jem.20031080","article-title":"c-FLIP mediates resistance of Hodgkin\/Reed-Sternberg cells to death receptor-induced apoptosis","volume":"199","author":"Mathas","year":"2004","journal-title":"J.\u00a0Exp. Med."},{"key":"10.1016\/j.canlet.2016.12.010_bib18","doi-asserted-by":"crossref","first-page":"7086","DOI":"10.1158\/0008-5472.CAN-04-1498","article-title":"Persistent c-FLIP(L) expression is necessary and sufficient to maintain resistance to tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis in prostate cancer","volume":"64","author":"Zhang","year":"2004","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2016.12.010_bib19","doi-asserted-by":"crossref","first-page":"19","DOI":"10.3349\/ymj.2008.49.1.19","article-title":"FLIP as an anti-cancer therapeutic target","volume":"49","author":"Yang","year":"2008","journal-title":"Yonsei Med. J."},{"key":"10.1016\/j.canlet.2016.12.010_bib20","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1002\/ijc.26458","article-title":"Rocaglamide and a XIAP inhibitor cooperatively sensitize TRAIL-mediated apoptosis in Hodgkin's lymphomas","volume":"131","author":"Giaisi","year":"2012","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.canlet.2016.12.010_bib21","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1182\/blood.V99.5.1745","article-title":"Global gene expression profiling of multiple myeloma, monoclonal gammopathy of undetermined significance, and normal bone marrow plasma cells","volume":"99","author":"Zhan","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.canlet.2016.12.010_bib22","doi-asserted-by":"crossref","first-page":"26953","DOI":"10.1074\/jbc.272.43.26953","article-title":"FLICE is predominantly expressed as two functionally active isoforms, caspase-8\/a and caspase-8\/b","volume":"272","author":"Scaffidi","year":"1997","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.canlet.2016.12.010_bib23","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1074\/jbc.274.3.1541","article-title":"The role of c-FLIP in modulation of CD95-induced apoptosis","volume":"274","author":"Scaffidi","year":"1999","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.canlet.2016.12.010_bib24","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1038\/nrclinonc.2012.15","article-title":"Latest advances and current challenges in the treatment of multiple myeloma","volume":"9","author":"Mahindra","year":"2012","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.canlet.2016.12.010_bib25","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1186\/s13045-016-0282-1","article-title":"Novel agents in the treatment of multiple myeloma: a review about the future","volume":"9","author":"Naymagon","year":"2016","journal-title":"J.\u00a0Hematol. Oncol."},{"key":"10.1016\/j.canlet.2016.12.010_bib26","first-page":"2651","article-title":"Therapeutic suppression of translation initiation modulates chemosensitivity in a mouse lymphoma model","volume":"118","author":"Bordeleau","year":"2008","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.canlet.2016.12.010_bib27","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1016\/j.cell.2006.01.021","article-title":"The E3 ubiquitin ligase itch couples JNK activation to TNFalpha-induced cell death by inducing c-FLIP(L) turnover","volume":"124","author":"Chang","year":"2006","journal-title":"Cell"},{"key":"10.1016\/j.canlet.2016.12.010_bib28","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/j.molcel.2005.08.017","article-title":"Regulating the regulators: control of protein ubiquitination and ubiquitin-like modifications by extracellular stimuli","volume":"19","author":"Gao","year":"2005","journal-title":"Mol. Cell"},{"key":"10.1016\/j.canlet.2016.12.010_bib29","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1039\/c39820001150","article-title":"X-ray crystal structure of rocaglamide, a novel antileukemic 1H-cyclopenta[b]benzofuran from Aglaia elliptifolia","author":"King","year":"1982","journal-title":"J.\u00a0Chem. Soc. Chem. Commun."},{"key":"10.1016\/j.canlet.2016.12.010_bib30","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1038\/cdd.2009.42","article-title":"Rocaglamide sensitizes leukemic T cells to activation-induced cell death by differential regulation of CD95L and c-FLIP expression","volume":"16","author":"Zhu","year":"2009","journal-title":"Cell Death Differ."},{"key":"10.1016\/j.canlet.2016.12.010_bib31","doi-asserted-by":"crossref","first-page":"3350","DOI":"10.1021\/jo040120f","article-title":"Silvestrol and episilvestrol, potential anticancer rocaglate derivatives from Aglaia silvestris","volume":"69","author":"Hwang","year":"2004","journal-title":"J.\u00a0Org. Chem."},{"key":"10.1016\/j.canlet.2016.12.010_bib32","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/S0009-2797(98)00073-8","article-title":"Cytostatic mechanism and antitumor potential of novel 1H-cyclopenta[b]benzofuran lignans isolated from Aglaia elliptica","volume":"115","author":"Lee","year":"1998","journal-title":"Chem. Biol. Interact."},{"key":"10.1016\/j.canlet.2016.12.010_bib33","doi-asserted-by":"crossref","first-page":"e5223","DOI":"10.1371\/journal.pone.0005223","article-title":"Antitumor activity and mechanism of action of the cyclopenta[b]benzofuran, silvestrol","volume":"4","author":"Cencic","year":"2009","journal-title":"PLoS One"},{"key":"10.1016\/j.canlet.2016.12.010_bib34","unstructured":"K. Umezawa, T. Yamamoto, T. Koyano, Japanese Patent 9067375, (1997)."},{"key":"10.1016\/j.canlet.2016.12.010_bib35","doi-asserted-by":"crossref","first-page":"2378","DOI":"10.1016\/j.yexcr.2007.03.018","article-title":"Membrane expression of DR4, DR5 and caspase-8 levels, but not Mcl-1, determine sensitivity of human myeloma cells to Apo2L\/TRAIL","volume":"313","author":"G\u00f3mez-Benito","year":"2007","journal-title":"Exp Cell Res."}],"container-title":["Cancer Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383516307637?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383516307637?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,21]],"date-time":"2024-06-21T08:02:20Z","timestamp":1718956940000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0304383516307637"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,3]]},"references-count":35,"alternative-id":["S0304383516307637"],"URL":"https:\/\/doi.org\/10.1016\/j.canlet.2016.12.010","relation":{},"ISSN":["0304-3835"],"issn-type":[{"value":"0304-3835","type":"print"}],"subject":[],"published":{"date-parts":[[2017,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Rocaglamide breaks TRAIL-resistance in human multiple myeloma and acute T-cell leukemia in\u00a0vivo in a mouse xenogtraft model","name":"articletitle","label":"Article Title"},{"value":"Cancer Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.canlet.2016.12.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Ireland Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}